StreetInsider.com News Articles

Form 4 Zoetis Inc. For: Aug 31 Filed by: SACCARO JAMES

Wed, 02 Sep 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260902/27019663.html

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Wed, 02 Sep 2026 07:30:00 -0400

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET.

Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.

About Zoetis
Zoetis is the world’s leading animal health company, driven by

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Wed, 02 Sep 2026 07:30:00 -0400

About Zoetis
Zoetis is the world’s leading animal health company, driven by

Zoetis Inc. (ZTS) PT Lowered to $94 at TD Cowen

Tue, 25 Aug 2026 07:40:44 -0400

TD Cowen analyst Steve Scala lowered the price target on Zoetis Inc. (NYSE: ZTS) to $94.00 (from $104.00) while maintaining a Buy rating.

The analyst commented: "We lower our ZTS PT to $94 and reduce near-term 2026/27 estimates, reflecting declining clinic visits for U.S. K9 derm and parasiticides, price pressure, and competition. Our revised model assumes flat 2026 revenue and +1% EPS growth. Long-term outlook still compelling, with a projected +4% revenue and +8% EPS CAGR 2025-32, driven by OA pain, livestock, pipeline launches, and buybacks."

Zoetis Inc. (ZTS) PT Lowered to $94 at TD Cowen

Tue, 25 Aug 2026 07:40:44 -0400

TD Cowen analyst Steve Scala lowered the price target on Zoetis Inc. (NYSE: ZTS) to $94.00 (from $104.00) while maintaining a Buy rating.

Form 3 Zoetis Inc. For: Aug 17 Filed by: SACCARO JAMES

Mon, 24 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260824/26968555.html

Form 3 Zoetis Inc. For: Aug 17 Filed by: SACCARO JAMES

Mon, 24 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260824/26968555.html

Zoetis Inc. (ZTS) PT Lowered to $80 at Stifel as Key Franchise Price Realization Decelerates

Thu, 20 Aug 2026 07:57:41 -0400

Stifel analyst Jonathan Block lowered the price target on Zoetis Inc. (NYSE: ZTS) to $80.00 (from $85.00) while maintaining a Hold rating.

The analyst commented, "For Zoetis, “Key Franchises” are comprised of Dermatology and the Simparica Family as well as OA pain mAbs, and accounts for ~40% of 2026E total revenue. In the 10-Q, Zoetis disclosed that 2Q26 Key Franchise volume growth was down -3% y/y. This is in-line with 1Q26 (-3%), and a consistent deterioration from the levels seen in 2025. We explored Zoetis’ Key Franchise volume / price dynamic in our deep dive last week, which showed Zoetis’ Key

Zoetis Inc. (ZTS) PT Lowered to $80 at Stifel as Key Franchise Price Realization Decelerates

Thu, 20 Aug 2026 07:57:41 -0400

Stifel analyst Jonathan Block lowered the price target on Zoetis Inc. (NYSE: ZTS) to $80.00 (from $85.00) while maintaining a Hold rating.

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio
Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

FDA grants emergency use for Simparica TRIO to treat screwworm in dogs

Thu, 13 Aug 2026 13:35:10 -0400

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Zoetis' (NYSE: ZTS) Simparica TRIO for the treatment of New World screwworm infestations in dogs and puppies, according to a press release statement.
Simparica TRIO, which contains sarolaner, moxidectin, and pyrantel, was originally approved by the FDA in 2020 for heartworm, flea, and tick-related indications. The new EUA does not authorize the product for prevention of New World screwworm, only for treatment.
The FDA stated it concluded that the known and potential benefits of Simparica TRIO outweigh its known and potential risks when used as authorized for this indication.
New

FDA grants emergency use for Simparica TRIO to treat screwworm in dogs

Thu, 13 Aug 2026 13:35:10 -0400

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Zoetis' (NYSE: ZTS) Simparica TRIO for the treatment of New World screwworm infestations in dogs and puppies, according to a press release statement.
Simparica TRIO, which contains sarolaner, moxidectin, and pyrantel, was originally approved by the FDA in 2020 for heartworm, flea, and tick-related indications. The new EUA does not authorize the product for prevention of New World screwworm, only for treatment.
The FDA stated it concluded that the known and potential benefits of Simparica TRIO outweigh its known and potential risks when used as authorized for this indication.
New

FDA grants emergency use for Simparica TRIO to treat screwworm in dogs

Thu, 13 Aug 2026 13:35:10 -0400

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Zoetis' (NYSE: ZTS) Simparica TRIO for the treatment of New World screwworm infestations in dogs and puppies, according to a press release statement.
Simparica TRIO, which contains sarolaner, moxidectin, and pyrantel, was originally approved by the FDA in 2020 for heartworm, flea, and tick-related indications. The new EUA does not authorize the product for prevention of New World screwworm, only for treatment.
The FDA stated it concluded that the known and potential benefits of Simparica TRIO outweigh its known and potential risks when used as authorized for this indication.
New

FDA: issues Emergency Use Authorization for Simparica Trio to treat new world screwworm in dogs & puppies

Thu, 13 Aug 2026 13:30:32 -0400

FDA: issues Emergency Use Authorization for Simparica Trio to treat new world screwworm in dogs & puppies